Lidamitol injection 100 + 2.5 mg / ml 1ml amp 10 pcs


Lidamitol injection 100 + 2.5 mg / ml 1ml amp 10 pcs



Active substance:
Tolperisone hydrochloride 100 mg
Lidocaine hydrochloride monohydrate (in terms of lidocaine hydrochloride) 2,5 mg
Methyl parahydroxybenzoate 0.6 mg
Propylene glycol 0.3 mg
0.1 M hydrochloric acid to pH 3.0-4.5
Water for injection ad 1 ml
Transparent colorless or colored liquid with a specific smell.
Product form:
Solution for intravenous and intramuscular administration of 100 mg / ml + 2.5 mg / ml.
To 1 ml ampoules (Politvist) of low density polyethylene, corresponding to the requirements of the European Pharmacopoeia to polyethylene for parenteral formulations, with the twist cap for a needleless sampling or preparation of colored glass ampoule.
Of 10 vials of low density polyethylene, together with instructions for use in a stack of cardboard.
10 ampoules of colored glass in blisters of polyvinyl chloride or polyethylene terephthalate film with a polymer film or lacquered aluminum foil, or without a polymeric film and aluminum foil patent or in the form of cardboard with cells for stacking ampoules.
2 contour cellular packaging made of cardboard or the shape of ampoules 10 together with instructions for use and a lancet ampulnam or without a pack of cardboard.
Hypersensitivity to any of the components of the preparation (including to lidocaine), myasthenia gravis, children up to 18 years, pregnancy, lactation (due to lack of data).
Precautions should use the drug in patients with renal or hepatic insufficiency. No dose adjustment is required.
100 mg + 2.5 mg / ml
– Symptomatic treatment of spasticity in adults caused by stroke.
– Treatment of painful muscle spasm associated with diseases of the musculoskeletal system (spondylosis, spondylarthrosis, cervical and lumbar syndromes).
Interaction with other drugs
No data on the interaction with drugs, limiting the use of the drug. Although tolperisone and affect the central nervous system, it does not cause sedation and therefore can be used in combination with sedatives, hypnotics and preparations containing ethanol.
It does not enhance the effect of ethanol on the CNS.
Enhances the effect of non-steroidal anti-inflammatory drugs, so while the appointment may require dose reduction of the latter.
Symptoms: ataxia, tonic and clonic convulsions, dyspnea and respiratory arrest.
Treatment: It is recommended the holding of symptomatic and supportive therapy. No specific antidote.
pharmachologic effect
Pharmacological group:
Muscle relaxants centrally acting.
Tolperisone hydrochloride is a central muscle relaxant. The exact mechanism of action is unknown. As a result of the action of membrane impedes excitation in primary afferent fibers, blocking mono- and polysynaptic spinal cord reflexes. Possibly, the secondary mode of action is to block transmitter release by blocking calcium ions entering the synapses.
Reduces reflex readiness reticulospinal pathways of the brain stem.
Strengthens the peripheral circulation. This action is not related to the effect of the drug on the central nervous system and may be due to a weak spasmolytic action and antiadrenergicheskim tolperisone.
Lidocaine hydrochloride possesses local anesthetic action and dosing system according Lidamitola action is not manual.
Tolperisone hydrochloride undergoes extensive metabolism in the liver and kidneys. Excreted by the kidneys, almost exclusively (> 99%) in the form of metabolites, pharmacological activity of which is unknown. When administered intravenously, the half-life of about 1.5 hours.
Lidocaine hydrochloride is completely absorbed (absorption rate depends on the site of administration and dose). Time to maximum concentration intramuscular injection – 30-45 minutes. Relationship to plasma proteins – 50-80%.
Rapidly distributed in tissues and organs. Penetrates the blood-brain barrier and the placental barrier, is secreted from breast milk (40% of maternal plasma concentrations).
It is metabolized in the liver (90-95%) with microsomal enzymes by dealkylation amino groups and cleavage of an amide bond to form active metabolites. Excreted in the bile (of the dose exposed reabsorption in the gut) and kidneys (10% unchanged).
Pregnancy and breast-feeding
The drug is contraindicated during pregnancy and in breast-feeding period (due to lack of data).
Conditions of supply of pharmacies
side effects
Classification of the incidence of side effects, recommended by the World Health Organization (WHO): very common (> 1/10), common (> 1/100 and
special instructions
The effect on the ability of control of vehicles and mechanisms
Caution should be exercised when driving vehicles and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Store at a temperature not higher than 15 degrees.
Keep out of the reach of children.
Dosing and Administration
The adult daily 1 ml, 2 times a day intramuscularly or 1 ml of 1 per day intravenously.
Working with the polymer ampoule:
1. Take a vial and shake it, holding it by the neck.
2. Rotate and rotate movements to separate the valve from the ampoule.
3. Through the hole immediately connect a syringe with luer ampoule.
4. Fill the syringe contents of the vial.
5. Push the needle on the syringe.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg

Grotex Ltd.

There are no reviews yet.

Add your review